Fundraising Fox
Anebulo Pharmaceuticals
OTC: ANEBLakeway, US · Founded 2020 · Delaware corporation · 3 known investors
Find your way into Anebulo Pharmaceuticals
Sign up to find every way you can get introduced to Anebulo Pharmaceuticals
- Your email: who you already know at Anebulo Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Anebulo Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Anebulo Pharmaceuticals is developing selonabant, a drug candidate intended to reverse cannabis-induced toxicities, including acute CNS depression in children and acute cannabinoid intoxication in adults. The company is a clinical-stage pharmaceutical developer targeting conditions for which there are no approved treatments.
Founders & leadership
Anebulo Pharmaceuticals was founded in 2020 by Joseph F. Lawler.
JF
Joseph F. LawlerFounder
DG
Daniel GeorgeExecutive
RA
Richard Anthony CunninghamChief Executive Officer
KC
Kenneth C. CundyChief Scientific Officer
Board
JA
Jason AryehBoard director
AR
Aron R. EnglishBoard director
KL
Kenneth LinBoard director
AK
Areta KupchykBoard director
BS
Bimal ShahBoard director
NC
Nathaniel CallowayBoard director
Investors · 3
Also in the syndicate · 2
22NWNantahala Capital
Reported raises · per SEC filings
Form D private placements$24.6M disclosed across 3 rounds · 2020–2024
▶$15MraisedDec 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedDec 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard CunninghamExecutive Officer, Director
- Daniel GeorgeExecutive Officer
- Jason AryehDirector
- Aron R. EnglishDirector
- Kenneth LinDirector
- Joseph F. LawlerDirector
- Areta KupchykDirector
- Bimal ShahDirector
- Nathaniel CallowayDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6.6MraisedOct 2022 · 5 investors · PharmaceuticalsRule 506(b)
▶$6.6MraisedOct 2022 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Areta KupchykDirector
- Joseph F. LawlerDirector
- Simon AllenExecutive Officer, Director
- Jason AryehDirector
- Kenneth LinDirector
- James R. MerchantExecutive Officer
- Karah ParschauerDirector
- Aron R. EnglishDirector
- Kenneth C. CundyExecutive Officer
- Offering amount
- $16.2M
- Amount sold
- $6.6M
- Sales commissions
- $150K
- Placement agents
- MTS Securities, LLC
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3MraisedJun 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJun 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Aron EnglishDirector
- Joseph F. LawlerExecutive Officer, Director
- Offering amount
- $5.3M
- Amount sold
- $3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$162.9Mvaluation at IPOMay 2021 · $7.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
Mission BioCapital Platinum Program Holdings LLCMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Anebulo Pharmaceuticals.
Frequently asked questions
- What does Anebulo Pharmaceuticals do?
- Anebulo Pharmaceuticals is developing selonabant, a drug candidate intended to reverse cannabis-induced toxicities, including acute CNS depression in children and acute cannabinoid intoxication in adults. The company is a clinical-stage pharmaceutical developer targeting conditions for which there are no approved treatments.
- Who founded Anebulo Pharmaceuticals?
- Anebulo Pharmaceuticals was founded by Joseph F. Lawler in 2020.
- Who are Anebulo Pharmaceuticals's investors?
- Anebulo Pharmaceuticals's investors include Merida Capital Holdings.
- How much funding has Anebulo Pharmaceuticals raised?
- Anebulo Pharmaceuticals has disclosed $24.6M raised across 3 rounds.
- Where is Anebulo Pharmaceuticals headquartered?
- Anebulo Pharmaceuticals is headquartered in Lakeway, US.